Last Updated2026-06-02

Market View

₹590(▼2.67%)

Reporting PeriodQ4 FY26

LINCOLNLINCOLN Forensic Risk Analysis

Name: LINCOLN Structural Risk Analysis
Creator: Flagium AI
License: https://creativecommons.org/licenses/by-nc-nd/4.0/

Pharmaceuticals

Risk ClassStable

Market CapN/A

Primary DriverEarnings Quality

Flagium AI Risk Score

15 / 100

-5 QoQ

Improving

Sentinel Insight

Financial profile remains stable for now. Pressure is receding in profitability and earnings quality. This indicates that forensic pressure is currently receding. Risk levels are improving.

40.4th %ile (Sector)Accel: +0 Qtrs

Updated2026-06-02

Market View

₹590▼2.67%

PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Earnings Quality

+10.8 pts

Stability Adjustment

+4.0 pts

Final Composite Risk15 / 100

Investment Risk Thesis

Historical Trend

Current risk score has risen from 5 → 15 over 13 quarters.

Expected Direction

🟢 Improving

Primary Deterioration Drivers

Margin Compression
Inventory Stress
Industrial Margin Stress

What to Watch Next Quarter

Operating profit margins
Debt growth
Inventory turnover

Active Risk Objects (7)

CriticalHigh

Margin Compression

📊 Earnings QualityAnnualActive for 2 Years

More Detail

Impact Weight15/15

MomentumDecaying

Last SignalQ4 FY2025

Operating margin declined by 4.8 bps YoY for two consecutive quarters.

"Operating efficiency is stabilizing. The rate of margin deterioration has slowed."

Industrial Margin Stress

📊 Earnings QualityAnnualActive for 3 Years

More Detail

Impact Weight12/15

MomentumPersistent

Last SignalQ4 FY2026

LINCOLN: Raw material costs consumed an additional 6.8% of revenue YoY.

"Margins are in freefall. Operating costs are growing significantly faster than revenue."

Operating Leverage Stress

📊 Earnings QualityAnnualActive for 2 Years

More Detail

Impact Weight10/15

MomentumDecaying

Last SignalQ4 FY2025

Expenses are consistently growing faster than revenues, creating operational pressure.

"Debt servicing metrics have improved recently. The company is actively deleveraging."

Inventory Stress

📊 Earnings QualityAnnualActive for 1 Years

More Detail

Impact Weight15/15

MomentumDecaying

Last SignalQ2 FY2025

Inventory growth (29.3%) significantly outpaced revenue growth (4.0%).

"Inventory overhang is clearing. Stock levels are normalizing as sales momentum returns."

Cash Conversion Deficit

📊 Earnings QualityAnnualActive for 2 Years

More Detail

Impact Weight6/15

MomentumDecaying

Last SignalFY2025

LINCOLN: OCF below Net Profit in 2/3 recent years.

"Cash conversion has normalized in the latest period. Operational cash flow is back in sync."

Relative Growth Weakness

📊 Earnings QualityAnnualActive for 4 Years

More Detail

Impact Weight12/15

MomentumPersistent

Last SignalQ2 FY2026

Revenue growth consistently lags behind sector median (12.8%).

"Early signs of earnings quality decay. Profitability is being driven by non-core items."

Working Capital Expansion

💧 Liquidity & CoverageAnnualActive for 2 Years

More Detail

Impact Weight10/15

MomentumDecaying

Last SignalQ4 FY2025

Working capital expansion detected: Receivable days increased by -4.7%.

"Working capital pressure is receding. Cash previously locked in operations is being released."

Risk Trajectory

Loading Chart

Resilience Matrix

Metric	Value	vs Sector	Signal
Volatility (σ)	5.83	7.70	✅ RESILIENT
Sensitivity (ε_s)	1	1.00	✅ RESILIENT
Escalation Prob.	5%	5%	✅ NEUTRAL
Safety Buffer	+51.0	+47.0	✅ RESILIENT

Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart

Share Price

Risk Score (0-100)

Market Performance

₹590(-2.67%)

1M Divergence-10.91%

1 Week-21.06%

1 Month-8.64%

6 Months+19.17%

1 Year+8.12%

2 Year+4.82%

3 Year+56.94%

Sector Average (1M)+2.27%

Sentinel Forensic Assessment

ALGORITHMIC RISK PROFILE • NON-ADVISORY

The structural architecture is currently robust. Capital resilience buffers in earnings quality remain well-maintained against forensic benchmarks. Systematic scans of operational margins and profitability metrics confirm the absence of material structural stress. Initial structural recovery is visible; monitor for a sustained return to resilience.

LINCOLN • MARKET STRUCTURE

Stage 2 — Advancing

The company is in a growth phase. Institutional sentiment is highly positive, supported by strong fundamentals and sustained risk reduction.

Stage Transition Prob.96%

Trend QualityDeveloping

Phase Progression

Phase Progression Score65%

Readiness LabelModerate (Transition Potential Building)

Probability of Advancing96%

CoinTree Momentum

Composite Z-Score-0.4223σ

Weakening momentum trend

Universe Rank#1927 of 2716

Top 70.95% in momentum strength

Timeframe Sparklines

1W-21.1%

1M-8.6%

6M+19.2%

Weinstein Indicators

150 DMA₹559.69

200 DMA₹555.73

150 DMA Slope+3.6896%Rising

Relative Strength+23.69%Leading

Relative Turnover (RTR)2.6252

ParticipationHealthy

PEER COMPARISON

Ranked comparison against sector peers

Risk profile is broadly in line with the Sector Mean (19).

Ticker	Risk Score	Sector %ile	Delta	Flags	Accel	Primary Driver
LINCOLNLINCOLN	15	40th	-5	7	+0	Earnings QualityStable
AAREYDRUGSAarey Drugs & Pharmaceuticals Limited	23	63th	-5	20	+0	Balance Sheet StressWatch
AARTIPHARMAarti Pharmalabs Limited	35	81th	0	18	+0	Earnings QualityWatch
ALBERTDAVDAlbert David Limited	37	90th	-8	27	+0	Balance Sheet StressWatch